Vitrolife Group makes an impairment charge of SEK 4.3 billion relating to Igenomix and provides preliminary financials for the fourth quarter 2023
· Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021. · Igenomix, now known as the business area Genetic Services, remains a core part of the new corporate strategy for the Vitrolife Group, however we have challenges to navigate in the short term. · Vitrolife Group also announces preliminary figures for Q4, with sales of SEK 904 million, corresponding to 6% growth in SEK, gross margin of 56.9% and EBITDA margin of 32.5%. Non-cash impairment charge Vitrolife Group (NASDAQ: